ArticleHuman vaccines & immunotherapeutics2012
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.
Article in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.Journal of immunology research · 2016Trial
- Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.Cancer medicine · 2025Review
- Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives.Biomolecules · 2025Review
- Review
- Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model.Cancer immunology, immunotherapy : CII · 2025Article
- Cancer Drug Targeting: Molecular Mechanism, Approaches, and Regulatory Framework.Current pharmaceutical design · 2025Review
- Advances in bio-immunotherapy for castration-resistant prostate cancer.Journal of cancer research and clinical oncology · 2023Review
- Vaccines as treatments for prostate cancer.Nature reviews. Urology · 2023Review
- Emerging Trends in Immunotherapy for Adult Sarcomas.The oncologist · 2023Article
- Anti-cancer peptide-based therapeutic strategies in solid tumors.Cellular & molecular biology letters · 2022Article
- Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities.Vaccines · 2021Review
- Review
- Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.Frontiers in oncology · 2020Review
- Development of Lobular Panniculitis Long After Completing the Personalized Peptide Vaccine Therapy.The American journal of case reports · 2018Article
- Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.Cancer science · 2018Article
- Personalized peptide vaccines and their relation to other therapies in urological cancer.Nature reviews. Urology · 2017Review
- Peptide-Based Treatment: A Promising Cancer Therapy.Journal of immunology research · 2015Review
- Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.World journal of gastroenterology · 2014Review
- Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.Journal for immunotherapy of cancer · 2014Article
- Current status of immunotherapy for the treatment of biliary tract cancer.Human vaccines & immunotherapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since both tumor cells and immune cell repertoires are diverse and heterogeneous, immune responses against tumor-associated antigens might be substantially different among individual patients. Personalized selection of right peptides for individuals could thus be an appropriate strategy for cancer vaccines. We have developed a novel immunotherapeutic approach, personalized peptide vaccination (PPV), in which HLA-matched peptides are selected and administered, based on the pre-existing host immunity before vaccination. Recent clinical trials of PPV have demonstrated a feasibility of this new therapeutic approach in various types of advanced cancers. For example, a randomized phase II trial for patients with castration resistant prostate cancer showed a possible clinical benefit in the PPV group. In the patients undergoing PPV, lymphocyte counts, increased IgG responses to the vaccine peptides, and inflammatory factors in pre-vaccination peripheral blood might be potential biomarkers for prognosis. Further randomized phase III trials would be recommended to prove clinical benefits of PPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.